Pyrosequencing of a hypervariable region in the internal transcribed spacer 2 to identify clinical yeast isolates

Mycoses

Volumn 55, Issue 2, 2012, Pages 172-180

  Pannanusorn, Srisuda ^a,b   Elings, Marlene Axner ^a   Römling, Ute ^b   Fernandez, Victor ^a  

^a SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Candida spp.; Identification; ITS2; Pyrosequencing; Yeast

Indexed keywords

INTERNAL TRANSCRIBED SPACER 2; NUCLEOTIDE;

ARTICLE; CANDIDA ALBICANS; CANDIDA GLABRATA; CONTROLLED STUDY; FUNGAL STRAIN; FUNGUS IDENTIFICATION; FUNGUS ISOLATION; GENE AMPLIFICATION; MALASSEZIA PACHYDERMATIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PYROSEQUENCING; RHODOTORULA MUCILAGINOSA; SACCHAROMYCES CEREVISIAE; SPECIES IDENTIFICATION; YEAST;

BASE SEQUENCE; CANDIDA; CANDIDIASIS, INVASIVE; DATABASES, GENETIC; DERMATOMYCOSES; DNA, FUNGAL; DNA, INTERGENIC; GENETIC VARIATION; HUMANS; MALASSEZIA; MOLECULAR SEQUENCE DATA; MYCOLOGICAL TYPING TECHNIQUES; MYCOSES; POLYMERASE CHAIN REACTION; RHODOTORULA; SACCHAROMYCES CEREVISIAE; SEQUENCE ANALYSIS, DNA;

CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; MALASSEZIA PACHYDERMATIS; RHODOTORULA MUCILAGINOSA; SACCHAROMYCES CEREVISIAE;

EID: 84857233199     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/j.1439-0507.2011.02064.x     Document Type: Article

References (36)

1. Horn DL, Neofytos D, Anaissie EJ et al. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clin Infect Dis 2009; 48: 1695-703.
2. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003; 348: 1546-54.
3. Cuenca-Estrella M, Bernal-Martinez L, Buitrago MJ et al. Update on the epidemiology and diagnosis of invasive fungal infection. Int J Antimicrob Agents 2008; 32: S143-7.
4. Schaenman JM, Rosso F, Austin JM et al. Trends in invasive disease due to Candida species following heart and lung transplantation. Transpl Infect Dis 2009; 11: 112-21.
5. Castón-Osorio JJ, Rivero A, Torre-Cisneros J. Epidemiology of invasive fungal infection. Int J Antimicrob Agents 2008; 32: S103-9.
6. Enoch DA, Ludlam HA, Brown NM. Invasive fungal infections: a review of epidemiology and management options. J Med Microbiol 2006; 55: 809-18.
7. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24, 179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39: 309-17.
8. Bedini A, Venturelli C, Mussini C et al. Epidemiology of candidaemia and antifungal susceptibility patterns in an Italian tertiary-care hospital. Clin Microbiol Infect 2006; 12: 75-80.
9. Roilides E, Farmaki E, Evdoridou J et al. Neonatal candidiasis: analysis of epidemiology, drug susceptibility, and molecular typing of causative isolates. Eur J Clin Microbiol Infect Dis 2004; 23: 745-50.
10. Snydman DR. Shifting patterns in the epidemiology of nosocomial candida infections. Chest 2003; 123: S500-3.
11. Hajjeh RA, Sofair AN, Harrison LH et al. Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program. J Clin Microbiol 2004; 42: 1519-27.
12. Perea S, Patterson TF. Antifungal resistance in pathogenic fungi. Clin Infect Dis 2002; 35: 1073-80.
13. Campbell CK, Davey KG, Holmes AD, Szekely A, Warnock DW. Comparison of the API Candida system with the AUXACOLOR system for identification of common yeast pathogens. J Clin Microbiol 1999; 37: 821-3.
14. Heelan JS, Sotomayor E, Coon K, D'Arezzo JB. Comparison of the rapid yeast plus panel with the API20C yeast system for identification of clinically significant isolates of Candida species. J Clin Microbiol 1998; 36: 1443-5.
15. Deák R, Bodai L, Aarts HJM, Maráz A. Development of a novel, simple and rapid molecular identification system for clinical Candida species. Med Mycol 2004; 42: 311-8.
16. Lau A, Sorrell TC, Chen S, Stanley K, Iredell J, Halliday C. Multiplex tandem PCR: a novel platform for rapid detection and identification of fungal pathogens from blood culture specimens. J Clin Microbiol 2008; 46: 3021-7.
17. Trama JP, Mordechai E, Adelson ME. Detection and identification of Candida species associated with candida vaginitis by real-time PCR and pyrosequencing. Mol Cell Probes 2005; 19: 145-52.
18. Ciardo DE, Schär G, Böttger EC, Altwegg M, Bosshard PP. Internal transcribed spacer sequencing versus biochemical profiling for identification of medically important yeasts. J Clin Microbiol 2006; 44: 77-84.
19. Leaw SN, Chang HC, Sun HF, Barton R, Bouchara JP, Chang TC. Identification of medically important yeast species by sequence analysis of the internal transcribed spacer regions. J Clin Microbiol 2006; 44: 693-9.
20. TM technology. Mycoses 2004; 47: 29-33.
21. Moder KA, Layer F, König W, König B. Rapid screening of clarithromycin resistance in Helicobacter pylori by pyrosequencing. J Med Microbiol 2007; 56: 1370-6.
22. Borman AM, Linton CJ, Oliver D, Palmer MD, Szekely A, Johnson EM. Rapid molecular identification of pathogenic yeasts by pyrosequencing analysis of 35 nucleotides of internal transcribed spacer 2. J Clin Microbiol 2010; 48: 3648-53.
23. Borman AM, Linton CJ, Oliver D et al. Pyrosequencing analysis of 20 nucleotides of internal transcribed spacer 2 discriminates Candida parapsilosis, Candida metapsilosis, and Candida orthopsilosis. J Clin Microbiol 2009; 47: 2307-10.
24. Boyanton JBL, Luna RA, Fasciano LR, Menne KG, Versalovic J. DNA pyrosequencing-based identification of pathogenic Candida species by using the internal transcribed spacer 2 region. Arch Pathol Lab Med 2008; 132: 667-74.
25. Montero C, Shea Y, Jones P et al. Evaluation of Pyrosequencing® technology for the identification of clinically relevant non-dematiaceous yeasts and related species. Eur J Clin Microbiol Infect Dis 2008; 27: 821-30.
26. Royo JL, Hidalgo M, Ruiz A. Pyrosequencing protocol using a universal biotinylated primer for mutation detection and SNP genotyping. Nat Protocols 2007; 2: 1734-9.
27. Vilela MMS, Kamei K, Sano A et al. Pathogenicity and virulence of Candida dubliniensis: comparison with C. albicans. Med Mycol 2002; 40: 249-57.
28. Putignani L, Paglia MG, Bordi E, Nebuloso E, Pucillo LP, Visca P. Identification of clinically relevant yeast species by DNA sequence analysis of the D2 variable region of the 25-28S rRNA gene. Mycoses 2008; 51: 209-27.
29. Valenza G, Strasen J, Schäfer F, Frosch M, Kurzai O, Abele-Horn M. Evaluation of new colorimetric Vitek 2 yeast identification card by use of different source media. J Clin Microbiol 2008; 46: 3784-7.
30. Sanguinetti M, Porta R, Sali M et al. Evaluation of VITEK 2 and RapID Yeast Plus systems for yeast species identification: experience at a large clinical microbiology laboratory. J Clin Microbiol 2007; 45: 1343-6.
31. Tavanti A, Davidson AD, Gow NAR, Maiden MCJ, Odds FC. Candida orthopsilosis and Candida metapsilosis spp. nov. to replace Candida parapsilosis groups II and III. J Clin Microbiol 2005; 43: 284-92.
32. Silva AP, Miranda IM, Lisboa C, Pina-Vaz C, Rodrigues AG. Prevalence, distribution, and antifungal susceptibility profiles of Candida parapsilosis, C. orthopsilosis, and C. metapsilosis in a tertiary care hospital. J Clin Microbiol 2009; 47: 2392-7.
33. van Asbeck E, Clemons KV, Martinez M, Tong AJ, Stevens DA. Significant differences in drug susceptibility among species in the Candida parapsilosis group. Diagn Microbiol Infect Dis 2008; 62: 106-9.
34. Sorrell TC. Cryptococcus neoformans variety gattii. Med Mycol 2001; 39: 155-68.
35. Jordan JA, Jones-Laughner J, Durso MB. Utility of pyrosequencing in identifying bacteria directly from positive blood culture bottles. J Clin Microbiol 2009; 47: 368-72.
36. Luna RA, Fasciano LR, Jones SC, Boyanton JBL, Ton TT, Versalovic J. DNA pyrosequencing-based bacterial pathogen identification in a pediatric hospital setting. J Clin Microbiol 2007; 45: 2985-92.